Navigation Links
Onyx Pharmaceuticals Announces First Quarter 2008 Financial Results Teleconference and Webcast
Date:4/29/2008

EMERYVILLE, Calif., April 29 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will webcast a teleconference with management to discuss first quarter 2008 financial results and provide a general business overview on Tuesday, May 6, 2008, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Financial results for the first quarter ended March 31, 2008 will be released earlier that day.

Interested parties may access a live webcast of the presentation on our website at: http://www.onyx-pharm.com/wt/page/event_calendar or by dialing 630-691-2760 and using the passcode 21488196. A replay of the presentation will be available on the Onyx website or by dialing 630-652-3044 and using the passcode 21488196 approximately one hour after the teleconference concludes. The replay will be available through June 6, 2008.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer by changing the way cancer is treated(TM). The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar(R), a small molecule drug. Nexavar is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in non-small cell lung cancer, melanoma, breast cancer, and other cancers. For more information about Onyx, visit the company's website at http://www.onyx-pharm.com.

Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer Pharmaceuticals Corporation.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Core Informatics Delivers Enterprise Core LIMS Installation to BioRelix Pharmaceuticals
2. Syndexa Pharmaceuticals Corporation and ChemDiv, Inc. Announce Discovery Collaboration
3. Aida Pharmaceuticals, Inc. Announces Update on Progress of Rh-Apo2L Testing
4. Schering-Plough/MERCK Pharmaceuticals Receives Not-Approvable Letter from FDA for Loratadine/Montelukast
5. Keryx Biopharmaceuticals Receives Nasdaq Notification
6. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
7. Idenix Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Aida Pharmaceuticals, Inc. Announces Completion of Research Institute Acquisition
9. Anadys Pharmaceuticals to Report First Quarter 2008 Financial Results
10. New Fragment-based Drug Discovery Platform Announced Between IOTA Pharmaceuticals Ltd, Cambridge (UK), and Beactica AB, Uppsala (Sweden)
11. MacroChem Acquires Virium Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... ... more and more E&L expertise. Within Albany Molecular Research, Inc. (AMRI), the scientific ... the past year and is planned for further growth in 2017. Extractable & ...
(Date:1/18/2017)... ... January 18, 2017 , ... MYOLYN, which creates medical ... submitted a 510(k) to the FDA, requesting clearance of the MyoCycle Home and ... (FES) technology. , The submission marks a major milestone for the technology ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... SCOPE Summit for Clinical Ops Executives (Hyatt Regency Miami, January 24-26). DrugDev will ... vital clinical research issues such as trial performance metrics, patient enrollment diversity, protocol ...
(Date:1/18/2017)... ... January 18, 2017 , ... uBiome, ... latest paper by its Science Editor, Dr. Elisabeth Bik, in the December 2016 ... Dr. Bik joined uBiome in October 2016 from her previous position at Stanford ...
Breaking Biology Technology:
(Date:12/16/2016)... Dec. 16, 2016   IdentyTechSolutions America LLC ... products and solutions and a cutting-edge manufacturer of ... it is offering seamless, integrated solutions that comprise ... products. The solutions provide IdentyTech,s customers with combined ... facilities from crime and theft. "We ...
(Date:12/16/2016)... -- The global wearable medical device market, in terms of value, ... 5.31 billion in 2016, at a CAGR of 18.0% during the ... ... medical devices, launch of a growing number of smartphone-based healthcare apps ... providers, and increasing focus on physical fitness. Furthermore, ...
(Date:12/15/2016)... Dec. 15, 2016   WaferGen Bio-systems, Inc. ... technology company, announced today that on December 13, 2016, ... of The Nasdaq Stock Market LLC which acknowledged that, ... of WaferGen,s common stock had been at $1.00 or ... regained compliance with Listing Rule 5550(a)(2) of the Nasdaq ...
Breaking Biology News(10 mins):